Nachum Kaplan
Corporate Officer/Principal presso Tel-Aviv University
Profilo
Nachum Kaplan currently works at Tel-Aviv University, as Member from 1989.
Dr. Kaplan also formerly worked at Affinium Pharmaceuticals Ltd., as Vice President-Microbiology from 2002 to 2013.
Dr. Kaplan received his doctorate degree from Tel-Aviv University.
Posizioni attive di Nachum Kaplan
| Società | Posizione | Inizio |
|---|---|---|
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | Corporate Officer/Principal | 21/04/2010 |
Precedenti posizioni note di Nachum Kaplan
| Società | Posizione | Fine |
|---|---|---|
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Chief Tech/Sci/R&D Officer | - |
Formazione di Nachum Kaplan
| Tel-Aviv University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
- Borsa valori
- Insiders
- Nachum Kaplan
